The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.
Novo CEO tells CNBC why drugmaker is rebranding, needs to ‘rethink’ obesity strategy
Skip to content
Your Best Financial And Money Saving Tips